openPR Logo
Press release

Protagen and OncoTyrol form strategic alliance to validate the UNIarray® technology platform

06-11-2009 03:13 PM CET | Health & Medicine

Press release from: Protagen AG

/ PR Agency: Biotech Consulting
Dortmund, Germany and New Jersey, USA, June 10, 2009. Protagen AG and the Medical University Innsbruck, Department of Urology, have recently identified autoantigen candidates present in serum of patients with prostate cancer using the proprietary UNIArray® technology platform. In Europe, prostate cancer is the second most frequent lethal malignancy in men. Yearly about 40,000 men die of prostate cancer in the European Union.

Current standard of screening for prostate cancer is focused on serum Prostate Specific Antigen (PSA) in combination with Digital Rectal Exam. Although routine PSA screening has resulted in earlier detection of prostate cancer, PSA levels can be elevated due to other conditions such as non-specific prostatitis and benign prostatic hyperplasia. A major disadvantage of the PSA marker is its low specificity, resulting in a significant amount of false biopsy indications. The novel test of Protagen targets the intermediate patient risk group, which requires frequent urological intervention (PSA range 2.5 ng/ml – 4.0 ng/ml). This validation study represents the next step in determining the most robust combination of putative prostate cancer markers and optimizing the diagnostic protein biochip to proceed to clinical trials, says Dr. Stefan Müllner, CEO of Protagen AG.

The UNIarray® technology platform of Protagen allows the development of novel diagnostics based on indication-specific autoantibody patterns in blood samples from patients. These autoantibody patterns are not only present in several autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals. Therefore, the systematic and indication-specific determination of autoantibody patterns will serve as a unique basis to address hitherto unmet diagnostic needs. In addition, UNIarray® serves as platform for the development of product specific companion diagnostics and patient stratification for clinical studies. Protagen presently is focused on research at novel diagnostics for numerous oncology indications including Breast, Colon and Pancreas, Multiple Sclerosis, Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Morbus Parkinson, and Alzheimer´s Disease.

About Protagen AG
Protagen AG (www.protagen.de) is a leading provider of products, services and software solutions for protein research with sites in Dortmund, Germany, and Chester, New Jersey, USA. Technology innovations of Protagen are UNIclone®, a patented platform for development and use of protein expression libraries, and UNIchip®, a versatile and highly efficient family of products for the development of antibodies, as well as UNIarray®, unique technology base for the development of new diagnostics.

About OncoTyrol
The K1 project for Personalized Cancer Medicine (OncoTyrol) has a project volume of €28 Mio over the next 4 years. The vision of OncoTyrol is to harness the benefits of the molecular revolution in cancer medicine by translating genomic, proteomic and metabolomic research into innovative, individualized and cost-effective approaches for cancer prevention, diagnosis and treatment. The consortium of researchers at the Biomedical Campus Innsbruck, which is close to three local universities and the University Hospital Innsbruck, together with national and international academic and industrial partners has joined efforts to develop and feed a pipeline of basic, translational, clinical and decision-analytic cancer research, and consequently establish a European center of excellence in cancer research with strong international visibility and an outstanding reputation. Due to the substantial scientific strengths and clinical expertise in breast and prostate cancer, chronic myeloid and lymphocytic leukemia, these paradigm malignancies were chosen as the primary targets of research. OncoTyrol research is supported by core facilities, which include technology platforms for genomic, epigenomic and proteomic profiling, SNP analysis and flow cytometry, a bioinformatics unit, tissue and serum banks, animal testing facilities and a clinical trial center within a comprehensive cancer center.

Contact
Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de

Media Enquiries
Dr. Holger Bengs
Biotech Consulting
Tel: +49 (0) 69 6199 4273
Fax: +49 (0) 69 6199 4249
E-Mail: info@holgerbengs.de

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Protagen and OncoTyrol form strategic alliance to validate the UNIarray® technology platform here

News-ID: 83389 • Views:

More Releases from Protagen AG

Protagen and Charles River form strategic partnership
Dortmund, Germany, October 28, 2011. Protagen AG, Dortmund, a GMP-certified specialist in the characterization of protein drugs and Charles River Laboratories International, Inc., one of the world leading companies in high-quality research models and preclinical and clinical support services, are pleased to announce a strategic Marketing & Sales alliance. For Charles River Biopharmaceutical Services (BPS) the fast-growing demand for biopharmaceuticals testing requires an expert partner with a broad range
Protagen meets with FDA
Dortmund, Germany and New Jersey, USA, February 19, 2009. Protagen AG, a leading provider of GMP compliant protein analytical services, protein bioinformatics, and protein biochips announces that it participated in two meetings with FDA personnel during the week of January 26, 2009. The meetings were intended to provide a detailed introduction to the company’s UNIarray® technology position and its potential use in the development of novel diagnostics for multiple sclerosis
Bayer HealthCare and Protagen sign a contract to evaluate the UNIarray® technol …
Dortmund, Germany and New Jersey, USA, December 3, 2008. Protagen AG announces the closing of a cooperation contract with Bayer HealthCare AG, Leverkusen, Germany, about the evaluation of the UNIarray® technology for discovery of novel biomarkers in atrial fibrillation. Bayer HealthCare is currently investigating atrial fibrillation after heart surgery in a clinical study. A certain number of patients develop this type of cardiac symptoms after surgery. Currently, it is not possible
Winner Consortium “NeuroAllianz” in the BioPharma Competition counts on UNIa …
Dortmund, Germany and New Jersey, USA, October 9, 2008: Protagen AG, a leading provider of GMP compliant protein analytical services, protein bioinformatics, and protein biochips has won the BMBF’s BioPharma competition jointly with consortium “NeuroAllianz”. The twelve project partners will develop therapeutic as well as diagnostic approaches in the field of neurodegenerative diseases from bench to market under the direction of Professor Christa E. Mueller and Professor Alexander Pfeifer. Protagen

All 5 Releases


More Releases for PSA

Professional Services Automation Market Competitive Analysis and Forecast 2017-2 …
Global Professional Services Automation Market: Snapshot The global market for professional services automation is expected to expand alongside the adoption of automation technologies across commercial units. Professional Services automation refers to the creation of automated systems for bill generation, expense monitoring, time tracking, and resource allocation in companies or businesses. Professional services automation offers a wide range of benefits to organizations in the form of reduced processing time, improved efficiency, satisfied
Professional Services Automation Market - Industry Potential & Key Players 2025 …
Global Professional Services Automation Market: Snapshot The global market for professional services automation is expected to expand alongside the adoption of automation technologies across commercial units. Professional Services automation refers to the creation of automated systems for bill generation, expense monitoring, time tracking, and resource allocation in companies or businesses. Professional services automation offers a wide range of benefits to organizations in the form of reduced processing time, improved efficiency, satisfied
Professional Services Automation Market – Future Growth Strategies 2025 | Fina …
Global Professional Services Automation Market: Snapshot The global market for professional services automation is expected to expand alongside the adoption of automation technologies across commercial units. Professional Services automation refers to the creation of automated systems for bill generation, expense monitoring, time tracking, and resource allocation in companies or businesses. Professional services automation offers a wide range of benefits to organizations in the form of reduced processing time, improved efficiency, satisfied customers,
Global PSA Software Market 2018: Promys, Appirio, ChangePoint, Projector PSA, Cl …
Global PSA Software Market 2018-2023 Industry News, Size, Share, Growth Rate, Trends Across The World The Global PSA Software Market 2018 present by QY News renders deep perception and offers the complete and entire analysis of the regional industry existing of the PSA Software market on a worldwide level. This study report mostly points on the basic regions such as North & South America, Europe, Africa, the Middle East, Asia and
PSA Software Market Global Outlook 2018: Accelo, HarmonyPSA, Tigerpaw Software, …
The report entitled Global PSA Software Market 2018 by QY Market Research offers a valuable tool to assess the latest PSA Software market statistics and market scenario. The report presents the strategies and research methodology followed to clarify the PSA Software industry aspects. This report analyses the crucial factors of the PSA Software market on the basis of present industry situations and concentrates on future prospects of PSA Software market
Global PSA Software Market 2017: ChangePoint, Projector PSA, Tenrox, Clarizen, D …
A new and latest research report PSA Software Market projected by QY Research renders deep perception of the key regional market and summary of the PSA Software Market industry on a global level. This widespread analysis comprises of market potentials and challenges, sales volume, PSA Software market revenue, estimates the rate of growth. This report especially focuses on the core regions such as North & South America, Europe, Africa, South